LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in LAVA Therapeutics NV as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +1 vs. Q3 2024
- Shares held
- 6.47M
- +2.86M (+79.4%) vs. Q3 2024
- Total value
- $6.15M
- +$163.9K (+2.7%) vs. Q3 2024
- New holders
- 8
- 5 more added
- Sold out
- 7
- 3 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TSFG, LLC | 400 | $0 | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 20 | $19 | 0.00% | +20 | New |
| SBI Securities Co., Ltd. | 300 | $285 | 0.00% | +300 | New |
| CIBC Private Wealth Group, LLC | 6,000 | $6.12K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 8,500 | $8.08K | 0.00% | −27,900−76.6% | Reduced |
| Two Sigma Securities, LLC | 13,157 | $12.5K | 0.00% | +13,157 | New |
| Geode Capital Management, LLC | 16,164 | $15.4K | 0.00% | +5,040+45.3% | Added |
| HRT Financial LP | 17,836 | $16.0K | 0.00% | +17,836 | New |
| UBS Group AG | 18,431 | $17.5K | 0.00% | +17,359+1,619.3% | Added |
| Millennium Management LLC | 19,604 | $18.6K | 0.00% | +7,541+62.5% | Added |
| Virtu Financial LLC | 19,916 | $19.0K | 0.00% | +813+4.3% | Added |
| Diadema Partners LP | 21,508 | $20.5K | 0.02% | +21,508 | New |
| Engineers Gate Manager LP | 31,985 | $30.4K | 0.00% | +20,095+169.0% | Added |
| BNP Paribas Arbitrage, SA | 41,800 | $39.8K | 0.00% | +41,800 | New |
| Two Sigma Investments, LP | 48,772 | $46.4K | 0.00% | −53,994−52.5% | Reduced |
| The PNC Financial Services Group, Inc. | 65,000 | $61.8K | 0.00% | 00.0% | Unchanged |
| Pathway Financial Advisors LLC | 102,500 | $97.5K | 0.02% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 126,328 | $120.1K | 0.02% | −20,129−13.7% | Reduced |
| Bruce & Co., Inc. | 771,874 | $733.3K | 0.24% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,149,345 | $1.09M | 0.42% | +1,149,345 | New |
| Sanofi | 1,919,455 | $1.83M | 1.05% | +1,919,455 | New |
| Redmile Group, LLC | 2,074,372 | $1.97M | 0.14% | 00.0% | Unchanged |
| Falcon Edge Capital, LP | 0 | $0 | 0.00% | −87,397−100.0% | Sold out |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −53,101−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −48,205−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −26,900−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −17,013−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −14,762−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −51−100.0% | Sold out |